Tim Harris
Tim is co-head of Osborne Clarke's international IP team. He is a highly regarded patent litigation partner who has a background in chemistry and specialises in the life sciences, pharmaceutical and biotechnology sectors.
Tim is currently advising Amgen in relation to its European and UK launches of several biosimilars including in relation to eculizumab (UK and UPC proceedings against Alexion) and aflibercept (UK proceedings against Regeneron and Bayer). In the past few years Tim has also represented Takeda, Allergan, Ascend and Anstar in UK patent proceedings. He has also recently advised Santen, AGC in relation to the patent strategy and freedom to operate aspects of some of their
key products in Europe including the UK.
Tim is a tutor on the Oxford University Postgraduate IP Diploma.
Tim is ranked in the Legal 500 as a ‘next generation’ pharma and biotech lawyer.